In addition, the researchers believe that SCD inhibition may reshift the balance of FA composition towards saturation, which exert a synergistic effect on HCC with sorafenib.120 Besides, inhibition of FAO by etomoxir or other methods (such as targeted delivery of CPT1A siRNA/shRNA) may limit the immunosuppressive function of M2 macrophages, which may be developed as an effective therapeutic strategy.48 Some immunotherapies related to lipid metabolism for cancers were summarized in Table 2. The gene discussed is CPT1A; the disease is cancer.